I'm starting to see more written about novel adjuvants being increasingly used in new vaccines. Today Isconova announced that it has signed a deal with Crucell for its nano-particle Matrix M adjuvant to be used in vaccines for HIV and malaria. Crucell already uses it in a flu program.
Matrix M is reported to increase both antibody-mediated and cellular immune responses, that in turn makes it attractive for use in a variety of vaccines. Results from a recent phase I avian flu study showed increased antibody secreting cells and polyfunctional CD4+ TH1 (t-helpers) cells -- with no serious side effects. See PBR.
Posted by Bruce Lehr June 9th 2011.